United Therapeutics Fires Back After Sandoz Files Anti-Competitive Lawsuit Over PAH Drug

United Therapeutics is taking on accusations that it is unfairly blocking competitors from launching generic versions of the company’s top-selling pulmonary arterial hypertension (PAH) drug, Remodulin.